Patrick Lally has over 15 years of healthcare investing experience. As a Partner at Petrichor, he oversees all investing activities, including origination, diligence, and asset management. He serves on the boards of Aurion Biotech, Corneagen, ITM, Persivia, and Vero. Previously, Patrick invested in healthcare special situations and structured finance at OrbiMed Advisors and focused on healthcare investments at Fortress Investment Group’s Drawbridge Special Opportunities Fund. He began his career at Barclays Capital in capital markets and leveraged finance. He holds an M.B.A. from Wharton and an A.B. in Molecular Biology from Princeton.